Effects of formulation and operating variables on Zanamivir dry powder inhalation characteristics and aerosolization performance

References

• Al-Asheh S, Jumah R, Banat F, Hammad S. (2003). The use of experimental factorial design for analysing the effect of spray dryer operating variables on the production of tomato powder. Food Bioprod Process 1:81–8
   Google Scholar
• Amaro MI, Tajber L, Corrigan OI, Healy AM. (2011). Optimisation of spray drying process conditions for sugar nanoporous microparticles (NPMPs) intended for inhalation. Int J Pharm 421:99–109
   PubMedGoogle Scholar
• Arakawa T, Tsumoto K, Kita Y, et al. (2007). Biotechnology applicationsof amino acids in protein purification and formulations. Amino Acids 33:587–605
   PubMed Web of Science ®Google Scholar
• Asada M, Takahashi H, Okamoto H, et al. (2004). Theophlline particle design using chitosan by the spray drying. Int J Pharm 270:167–74
   PubMed Web of Science ®Google Scholar
• British Pharmacopoeia Commission. (2005). Density of solids: Bulk and tapped density. British pharmacopoeia, Vol. 4, Appendix VQ. London: Her Majesty’s Stationery Office Ltd, A211–12
   Google Scholar
• Broadhead J, Rouan SKE, Hau I, Rhodes CT. (1994). The effect of process and formulation variables on the properties of spray dried β-galactosidase. J Pharm Pharmacol 46:458–67
   PubMed Web of Science ®Google Scholar
• Boshhiha AM, Urbanetz NA. (2009). Influence of carrier surface fines on dry powder inhalation formulations. Drug Dev Ind Pharm 35:904–16
   PubMed Web of Science ®Google Scholar
• Bosquillon C, Lombry C, Préat V, Vanbever R. (2001). Influence of formulation excipients and physical characteristics of inhalation dry powders on their aerosolization performance. J Control Rel 70:329–39
   PubMed Web of Science ®Google Scholar
• Bosquillon C, Rouxhet PG, Ahimou F, et al. (2004). Aerosolization properties, surface composition and physical state of spray-dried protein powders. J Control Rel 99:357–67
   PubMed Web of Science ®Google Scholar
• Chan HK, Clark AR, Feeley JC, et al. (2004). Physical stability of salmone calcitonin spray-dried powders for inhalation. J Pharm Sci 93:792–804
   PubMed Web of Science ®Google Scholar
• Chew NY, Shekunov BY, Tong HH, et al. (2005). Effect of amino acids on the dispersion of disodium cromoglycate powders. J Pharm Sci 94:2289–300
   PubMed Web of Science ®Google Scholar
• Chougule MB, Padhi BK, Jinturkar KA, Misra A. (2007). Development of dry powder inhalers. Recent Pat Drug Deliv Formul 1:11–21
   PubMedGoogle Scholar
• Cook RO, Pannu RK, Kellaway IW. (2005). Novel sustained release microsphere for pulmonary drug delivery. J Control Rel 104:79–90
   PubMed Web of Science ®Google Scholar
• Cox RJ, Mykkeltvedt E, Sjursen H, Haaheim LR. (2001). The effect of zanamivir treatment on the early immune response induced after influenza vaccination. Vaccine 19:4743–9
   PubMed Web of Science ®Google Scholar
• Daviskas E, Anderson SD, Eberl S, Young IH. (2008). Effect of increasing doses of mannitol on mucus clearance in patients with bronchectiasis. Eur Respir J 31:765–72
   PubMed Web of Science ®Google Scholar
• Donovan MJ, Gibbons A, Herpin MJ, et al. (2011). Novel dry powder inhaler particle-dispersion systems. Ther Deliv 2:1295–311
   PubMedGoogle Scholar
• European Commission Health & Consumer Protection Directorate. (2002). Provisional statement on the safety of calf-derived rennet for the manufacture of pharmaceutical grade lactose. Adopted by the scientific steering committee at its meeting of 4–5 April 2002. Directorate C – Scientific Opinions. C1 – Follow-up and dissemination of scientific opinions
   Google Scholar
• Food and Drug Administration. (1998). Draft guidance for industry on metered dose inhaler (MDI) and dry powder inhaler (DPI) drug products
   Google Scholar
• Glińiski J, Chavepeyer G, Platten JK. (2000). Surface properties of aqueous solutions of l-leucine. Biophys Chem 84:99–103
   PubMed Web of Science ®Google Scholar
• Hickey AJ, Concessio NM. (1997). Descriptors of irregular particle morphology and powder properties. Adv Drug Deliv Rev 26:29–40
   PubMed Web of Science ®Google Scholar
• Hickey AJ, Mansour HM, Telko MJ, et al. (2007). Physical characterization of component particles included in dry powder inhalers. I. Strategy review and static characteristics. J Pharm Sci 96:1282–301
   PubMed Web of Science ®Google Scholar
• Jaques A, Daviskaks E, Turton JA, et al. (2008). Inhaled mannitol improves lung function in cystic fibrosis. Chest 133:1388–96
   PubMed Web of Science ®Google Scholar
• Kaialy W, Martin GP, Ticehurst MD, et al. (2010). The enhanced aerosol performance of salbutamol from dry powders containing engineered mannitol as excipient. Int J Pharm 392:178–88
   PubMed Web of Science ®Google Scholar
• Lechuga-Ballesteros D, Charan C, Stults CL, et al. (2008). Trileucine improves aerosol performance and stability of spray-dried powders for inhalation. J Pharm Sci 97:287–302
   PubMed Web of Science ®Google Scholar
• Li HY, Seville PC, Williamson IJ, Birchall JC. (2005). The use of amino acids toenhance the aerosolization of spray-dried powders for pulmonary gene therapy. J Gene Med 7:343–53
   PubMed Web of Science ®Google Scholar
• Lucas P, Anderson K, Potter UJ, Staniforth JN. (1999). Enhancement of small particle size dry powder aerosol formulations using an ultra low density addictive. Pharm Res 16:1643–7
   PubMed Web of Science ®Google Scholar
• Maa YF, Costantino HR, Nguyen PA, Hsu CC. (1997). The effect of operating and formulation variables on the morphology of spray-dried protein particles. Pharm Dev Technol 2:213–23
   PubMed Web of Science ®Google Scholar
• Najafabadi AR, Gilani K, Barghi M, Rafiee-Tehrani M. (2004). The effect of vehicle on physical properties and aerosolisation behaviour of disodium cromoglycate microparticles spray dried alone or with l-leucine. Int J Pharm 285:97–108
   PubMed Web of Science ®Google Scholar
• Okamoto H, Danjo K. (2008). Application of supercritical fluid to preparation of powders of high-molecular weight drugs for inhalation. Adv Drug Deliv Rev 60:433–46
   PubMed Web of Science ®Google Scholar
• Pilcer G, Amighi K. (2010). Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm 392:1–19
   PubMed Web of Science ®Google Scholar
• Rabbani NR, Seville PC. (2005). The influence of formulation components on the aerosolisation properties of spray-dried powders. J Control Rel 110:130–40
   PubMed Web of Science ®Google Scholar
• Seville PC, Li HY, Learoyd TP. (2007). Spray-dried powders for pulmonary drug delivery. Crit Rev Ther Drug Carrier Syst 24:307–60
   PubMed Web of Science ®Google Scholar
• Shoyele SA, Cawthorne S. (2006). Particle engineering techniques for inhaled biopharmaceuticals. Adv Drug Deliv Rev 58:1009–29
   PubMed Web of Science ®Google Scholar
• Stahl K, Claesson M, Lilliehorn P, et al. (2002). The effect of process variables on the degradation and physical properties of spray dried insulin intended for inhalation. Int J Pharm 233:227–37
   PubMed Web of Science ®Google Scholar
• Steckel H, Bolzen N. (2004). Alternative sugars as potential carriers for dry powder inhalations. Int J Pharm 270:297–306
   PubMed Web of Science ®Google Scholar
• Todo H, Iida K, Okamoto H, Danjo K. (2003). Improvement of insulin absorption from intratracheally administrated dry powder prepared by supercritical carbon dioxide process. J Pharm Sci 92:2475–86
   PubMed Web of Science ®Google Scholar
• Wang L, Zhang Y, Tang X. (2009). Characterization of a new inhalable thymopentin formulation. Int J Pharm 375:1–7
   PubMed Web of Science ®Google Scholar
• You Y, Zhao M, Liu GL, Tang X. (2007). Physical characteristics and aerosolization performance of insulin dry powders for inhalation prepared by a spray drying method. J Pharm Pharmacol 59:927–34
   PubMed Web of Science ®Google Scholar